LabConnect Partners with Kits4Life to Advance Sustainability in Clinical Trials

As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce ...

August 08, 2025 | Friday | News
Sanofi Completes $470M Acquisition of Vigil Neuroscience to Strengthen Neurology Pipeline

Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition strengthens Sanofi’s ea...

August 07, 2025 | Thursday | News
Janux Therapeutics Achieves $10 Million Milestone as First Patient Dosed in Merck Collaboration Trial

First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (Nasdaq: JANX...

August 06, 2025 | Wednesday | News
Taiwan’s Anbogen Therapeutics Receives FDA IND Approval to Initiate Global Phase 1/2 Trial for ABT-301 in Metastatic Colorectal Cancer

Anbogen Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, ...

August 04, 2025 | Monday | News
Akeso Doses First Patient in Pivotal Phase III Trial of Ivonescimab for IO-Resistant NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMO...

July 31, 2025 | Thursday | News
Can-Fite’s Piclidenoson Shows Promise in Preclinical Vascular Dementia Study Led by UCLA Researchers

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule dr...

July 29, 2025 | Tuesday | News
CORXEL Submits NDA for LENZ Therapeutics’ LNZ100 in China, Marking First Global Regulatory Filing for Aceclidine-Based Eye Drop for Presbyopia

LENZ Therapeutics, Inc. a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidin...

July 29, 2025 | Tuesday | News
GH Research Reports 73% Remission in TRD with GH001; Global Pivotal Trial Set for 2026

Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months...

July 25, 2025 | Friday | News
Clearside Biomedical Secures Health Canada Approval for XIPERE® in Treating Uveitic Macular Oedema

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

July 25, 2025 | Friday | News
4TEEN4 Pharmaceuticals Doses First Patient in PROCARD1 Trial for Groundbreaking Shock Therapy

4TEEN4 Pharmaceuticals GmbH  announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal anti...

July 25, 2025 | Friday | News
Sygnature Discovery Doubles High-Throughput Chemistry Capacity with £1M Investment

  Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancemen...

July 24, 2025 | Thursday | News
HMNC and Spruce Launch Phase 2 TAMARIND Trial to Explore Precision Treatment for Depression

HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: S...

July 23, 2025 | Wednesday | News
Corteria Pharmaceuticals Advances Dual CRF2 Agonist Pipeline for Heart Failure and Obesity

Corteria Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of transformative therapies for heart failure and obesity, ...

July 22, 2025 | Tuesday | News
SpringWorks Wins EU Nod for EZMEKLY® in NF1-Related Tumours

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced  that the European Commission (EC) granted conditi...

July 21, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close